Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Contact Supplier

Jai Radhe Sales is your partner for all your sourcing needs.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

6 Drugs in Development

6 Drugs in Development

DIGITAL CONTENT

12 NEWS #PharmaBuzz

media
12 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

6DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 391210-10-9, Pd0325901, Pd 0325901, Pd-0325901, Mirdametinib, (r)-n-(2,3-dihydroxypropoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide

Molecular Formula

C₁₆H₁₄F₃IN₂O₄

Molecular Weight

482.19 g/mol

InChI Key

SUDAHWBOROXANE-SECBINFHSA-N

FDA UNII

86K0J5AK6M

Mirdametinib is an orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. Upon administration, mirdametinib selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors.

1 2D Structure

Mirdametinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide

2.1.2 InChI

InChI=1S/C16H14F3IN2O4/c17-11-3-2-10(16(25)22-26-7-9(24)6-23)15(14(11)19)21-13-4-1-8(20)5-12(13)18/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m1/s1

2.1.3 InChI Key

SUDAHWBOROXANE-SECBINFHSA-N

2.1.4 Canonical SMILES

C1=CC(=C(C=C1I)F)NC2=C(C=CC(=C2F)F)C(=O)NOCC(CO)O

2.1.5 Isomeric SMILES

C1=CC(=C(C=C1I)F)NC2=C(C=CC(=C2F)F)C(=O)NOC[C@@H](CO)O

2.2 Other Identifiers

2.2.1 UNII

86K0J5AK6M

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Mirdametinib

2. Pd 0325901

3. Pd 325901

4. Pd-0325901

5. Pd-325901

6. Pd0325901

7. Pd325901

2.3.2 Depositor-Supplied Synonyms

1. 391210-10-9

2. Pd0325901

3. Pd 0325901

4. Pd-0325901

5. Mirdametinib

6. (r)-n-(2,3-dihydroxypropoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide

7. Pd-325901

8. (r)-n-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide

9. Pd 325901

10. Mirdametinib [usan]

11. Pd325901

12. 86k0j5ak6m

13. Chembl507361

14. Chebi:88249

15. Pd 901

16. N-{[(2r)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide

17. Mirdametinib (usan)

18. Ncgc00189075-01

19. Pd 03525901

20. N-((r)-2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide

21. N-[((r)-2,3-dihydroxypropyl)oxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide

22. N-[(2r)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide

23. 391209-97-5

24. Unii-86k0j5ak6m

25. N-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide

26. 4bm

27. N-(((r)-2,3-dihydroxypropyl)oxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide

28. N-((2r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-benzamide

29. Mirdametinib [inn]

30. Dsstox_cid_24024

31. Dsstox_rid_80100

32. Dsstox_gsid_44024

33. Mirdametinib [who-dd]

34. Pd0325901(mirdametinib)

35. Schembl172904

36. Gtpl7935

37. Dtxsid0044024

38. Ex-a102

39. Bcpp000126

40. Bdbm104963

41. Hms3648a14

42. Amy36437

43. Zinc3938683

44. Tox21_113364

45. Mfcd09909925

46. Nsc755770

47. Nsc800840

48. S1036

49. Who 11299

50. Akos015855518

51. Bcp9001057

52. Ccg-221316

53. Cs-0062

54. Db07101

55. Ex-8602

56. Nsc-755770

57. Nsc-800840

58. Ncgc00381744-09

59. Hy-10254

60. Us8575391, Q

61. Bb 0261791

62. Cas-391210-10-9

63. Sw218101-2

64. D11675

65. Pd-0325901,pd325901

66. Pd 0325901, >=98% (hplc)

67. Pd0325901 (pd325901)

68. Sr-01000946344

69. J-502503

70. Sr-01000946344-1

71. Brd-k49865102-001-01-9

72. Q27088255

73. Insolution Mek1/2 Inhibitor Iii, Pd0325901 - Cas 391210-10-9

74. Benzamide,n-[(2r)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-

75. N-((r)-2,3-dihydroxy[propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide

76. N-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide

77. N-[(2r)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]- Benzamide

78. N-[(2r)-2,3-dihydroxypropoxy]-3,4-difluoro-2[(2-fluoro-4-iodophenyl)amino]-benzamide

79. (-)-n-(((r)-2,3-dihydroxypropyl)oxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide

80. N-(((r)-2,3-dihydroxypropyl)oxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide N-((2r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide

2.4 Create Date

2006-10-25

3 Chemical and Physical Properties

Molecular Formula	C₁₆H₁₄F₃IN₂O₄
Molecular Weight	482.19 g/mol
XLogP3	3
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	7
Exact Mass	481.99504 g/mol
Monoisotopic Mass	481.99504 g/mol
Topological Polar Surface Area	90.8 Å²
Heavy Atom Count	26
Formal Charge	0
Complexity	465
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1